Regulatory, Site Activation, Monitoring, Quality

Delays are too
risky for BIOTECH

Rosenbaum Research

Accelerated trials via
Transparent partnership​

Expert CRO, specialized in the Central Europe, Eastern Balkans and Türkiye , with​

Global approach and proven track record of completed trials

How?

Our services are flexible thanks to our Functional Service Provider (FSP Model)​ which works well for small and mid-sized Biotech with PIPELINE in development and CROs that need coverage in our region, that mainly have their own capabilities.
We provide tailor made solution for:

  • Feasibility and Site selection;
  • Regulatory and Ethics Committee Submission;
  • Site Start-up activities;
  • Safety Reporting;
  • Site contracts execution and budget negotiation;
  • Clinical monitoring;
  • Site and Project management;
  • Data management support;
  • Quality management support;
  • Investigator grant payment management;
  • Import and Export License execution;
  • Custom clearance clinical supply and equipment storage;
  • Türkiye Legal representation (KVKK/Verbis)

  • All services are on demand. Our team is operating according to client SOPs within the FSP Model.​

Our Exprience is defined by more than two dozens Clinical Trials completed in the past 6 years.

See trials

Founded in 2019, Rosenbaum Group has grown from an entrepreneurial vision into an operational team of over 20 professionals with experience across leading international CROs.
We specialize in navigating complex European regions, where operational expertise, local insight, and execution excellence make the difference between delay and delivery.
Our focus is clear: reliable outcomes, efficient patient recruitment, operational excellence, and a sustainable return on investment.

Why?

We know how important is to know Sites & Investigators when it comes to recruitment, quality and delivery.​

Through long‑standing professional relationships, we collaborate with a carefully selected group of investigators and site teams who share our commitment to quality and performance.
This close cooperation enables strong patient recruitment results, with enrollment goals often achieved on time. ​

Therapeutic areas

Gastroenterology

Inflammatory bowel disease (IBD): Ulcerative colitis (UC), Crohn’s disease (CD), fibrostenosing Crohn’s disease, pouchitis
Eosinophilic gastrointestinal diseases (EGIDs): Eosinophilic esophagitis (EoE)
Microscopic colitis
Celiac disease (CeD)
Functional and motility disorders of the gastrointestinal tract: Gastroparesis
Familial adenomatous polyposis (FAP)
Inflammatory liver conditions: Primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC)

Oncology

NSCLC, Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Advanced Melanoma

Multiple Sclerosis

Multiple Sclerosis, Spasticity, neuropathic pain and other neurological indications​

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.​

Cardiology

Heart Failure
Valvular heart disease
Dilative and Hypertrophic Cardiomyopathy
Chronic Myocarditis
Coronary Artery Disease & Atherosclerosis Cardiac Arrhythmia
Pulmonary Arterial Hypertension
Acute Ischemic Stroke

Psychiatry

Major Depressive Disorders, Schizophrenia & Schizoaffective, Agitation – Schizophrenia & Bipolar Disorders, Treatment-Resistant Depression

Autoimmune Diseases​

Rheumatoid Arthritis, Psoriatic Arthritis, lupus erythematosus, Psoriasis​

Covid-19 trials

Coverage

Albania
Austria
Bulgaria
Czech Republic
Denmark
Germany
Greece
Italy
Kosovo
Montenegro
Poland
Serbia
Slovakia
Türkiye

Rosenbaum Research Offices

Rosenbaum Research Operational presence

coverage map

Our CRO Model is approved by​ Reuters Pharma Awards​ and BIOTECH Industry

David Rosenbaum
David Rosenbaum